NVAX has been one of our best performing stocks that has been trading in an accumulation range between $7 and $9. I believe that NVAX is trending for an upward breakout in Q4. The FDA has approved NVAX's COVID vaccine for patient ages 12+, and the European Union is set to make a decision in October. I believe that NVAX has promising short-term outlook that will lead to a rally with a break above $9. So far $9.18 has been a key resistance target, but I believe that NVAX will ultimately break out to the light blue resistance level at $16.21
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在
使用条款阅读更多信息。